Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
CDR-Life's Experimental MS Therapy CDR111 Meets Preclinical Milestone
Experimental MS therapy CDR111, developed by CDR-Life and Boehringer Ingelheim, advances after meeting a key preclinical milestone in B-cell depletion.
Alzheimer’s Disease May Be an Autoimmune Condition, New Theory Suggests
A new theory proposes Alzheimer's is an autoimmune disease of the brain's immune system, challenging the 30-year-old beta-amyloid cascade hypothesis.
FoRx Therapeutics Unveils FORX-428 Preclinical Data at ACS Spring 2026
FoRx Therapeutics presents preclinical data at ACS Spring 2026 for FORX-428, a novel PARG inhibitor targeting treatment-resistant cancers.
FDA Approves Denali's Avlayah Drug for Hunter Syndrome: Rare Disease Win
The FDA approves Denali Therapeutics' Avlayah, the first enzyme replacement therapy addressing cognitive symptoms of Hunter syndrome, a rare genetic disease.
Biolojic Design Reaches Teva Milestone for AI-Designed Multibody TEV ‘325
Biolojic Design earns a preclinical milestone payment from Teva for TEV ‘325, a novel AI-designed multibody targeting autoimmune diseases like asthma.
FDA Grants Sanofi's Venglustat Breakthrough Therapy for Gaucher Type 3
Sanofi's oral medication Venglustat receives FDA Breakthrough Therapy status for Gaucher type 3, showing potential to manage neurological symptoms effectively.
Earendil Labs Lands $787M to Accelerate AI Biologics Development Push
Earendil Labs secures $787m backed by Sanofi to expand its AI-driven drug discovery platform and progress its pipeline of 40+ biologic programs.
MAIA Biotech Advances Ateganosine with Fast Track and Phase 3 NSCLC Trial
MAIA Biotechnology advances its lead cancer drug ateganosine (THIO) into Phase 3 trials for NSCLC, backed by Fast Track status and strong interim data.
ImmunityBio Wins Macau Approval for Anktiva Combo Therapy in Bladder Cancer
ImmunityBio receives Macau approval for Anktiva in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer.
MIRA’s Mira-55 Shows No THC-Like CNS Side Effects in Preclinical Trials
MIRA Pharmaceuticals reports positive preclinical data for Mira-55, demonstrating pain relief potential without THC-like CNS side effects or opioid risks.
J&J Wins FDA Approval for Icotyde to Enter Plaque Psoriasis Pill Market
The FDA has approved J&J's Icotyde (icotrokinra), the first oral peptide for moderate-to-severe plaque psoriasis in adults and pediatric patients 12+.
Omega Therapeutics Stock Jumps on Positive OP-101 Preclinical Cancer Data
Omega Therapeutics stock climbs as preclinical data for its lead epigenomic medicine, OP-101, shows up to 70% tumor reduction in solid cancer models.
30
31
32
33
34
35
36
37
38